TScan Therapeutics, Inc. (TCRX)
| Market Cap | 16.81M-87.5% |
| Revenue (ttm) | 7.11M |
| Net Income | -117.71M |
| EPS | -0.91 |
| Shares Out | 63.50M |
| PE Ratio | n/a |
| Forward PE | -0.43 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 331,082 |
| Open | 0.27 |
| Previous Close | 0.28 |
| Day's Range | 0.25 - 0.27 |
| 52-Week Range | 0.25 - 2.57 |
| Beta | 1.14 |
| Analysts | Hold |
| Price Target | 1.00(+303.23%) |
| Earnings Date | n/a |
Insiders here have filed 2 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About TCRX
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
$TCRX stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in TCRX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by TCRX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
TCRX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
TCRX Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Collaboration and license revenue | $1.05M | 55.79% |
| Interest and other income, net | $833.00K | 44.21% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New TCRX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to TCRX from public contracts
Source: USAspending.gov
TCRX Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from TCRX’s recent data — informational, not investment advice